ClinicalTrials.gg
RecruitingNCT06917911Updated Nov 4, 2026

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

A Phase 2 interventional study of Biospecimen Collection and Bone Marrow Aspiration in Core Binding Factor Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI). Recruiting at 81 sites in 2 countries. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 4, 2026First site in Puerto RicoStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies testing gemtuzumab in Leukemia, Myeloid, Acute — 6 open to participants now, 8 under way, 2 of them phase 3. Gemtuzumab · Leukemia, Myeloid, Acute.

Planned enrollment
16th of 56
162 · median 47
Started
2026
the only one that year
Phase 2
24 of 60
3 open now
Registered
60th of 60
by date
Lead sponsor
3 of 60
National Cancer Institute (NCI)

Among the 60 studies testing gemtuzumab in Leukemia, Myeloid, Acute, this one is the 16th largest by planned enrollment of the 56 interventional ones that give a count, is the only one that started in 2026, is one of 24 in phase 2, and was the 60th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

6 of the 60 studies testing gemtuzumab in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About gemtuzumab

Gemtuzumab: first FDA approval 2017 (MYLOTARG), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing gemtuzumab in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia (CBF-AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to an antitumor antibiotic drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with cytarabine and daunorubicin may have fewer side effects and be as effective or better than the combination with gemtuzumab ozogamicin in treating patients with core binding factor AML.

Read the detailed description

PRIMARY OBJECTIVE:

I. Compare the rates of complete remission (CR) without measurable residual disease (CRMRD-) by multiparameter flow cytometry following induction therapy between the two treatment arms in each cohort separately.

SECONDARY OBJECTIVES:

I. To compare the rates of CR and composite complete remission (CRc) (CR+complete remission with incomplete hematologic recovery [CRi]+complete remission with partial hematologic recovery [CRh]) between the treatment arms.

II. To compare the overall survival (OS) between the treatment arms. III. To compare the event-free survival (EFS). IV. To compare the cumulative incidence of relapse (CIR). V. To compare the cumulative incidence of death (CID) between the treatment arms.

VI. To compare the rate of early death at 30 days and 60 days between the treatment arms.

VII. To assess the rate and frequency of adverse events between treatment arms. VIII. To evaluate mutant RAS and mutant KIT as predictive biomarkers for CRMRD- rate in CBF AML.

EXPLORATORY OBJECTIVE:

I. To compare MRD (and its clinical implication, e.g., relapse rates) between flow cytometry (FC) and next generation sequencing (NGS)-based (RUNX1::RUNX1T1 or CBFB::MYH11).

CORRELATIVE OBJECTIVES:

I. To evaluate the frequency and clinical impact of variant allele frequency (VAF) of KIT mutation, KIT mutations in different exons (e.g., exon 8 or 17), CD33 expression, additional (secondary) mutations and cytogenetic abnormalities.

II. To evaluate the differences in clinical and molecular outcomes in patients with RUNX1::RUNX1T1 mutated versus CBFB::MYH11 mutated CBF AML.

OUTLINE: Patients are randomized to 1 of 2 regimens.

REGIMEN 1: Patients receive gemtuzumab ozogamicin intravenously (IV) on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or multigated acquisition (MUGA) scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.

REGIMEN 2: Patients receive venetoclax orally (PO) once daily (QD) on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.

After completion of study treatment, patients are followed up at relapse and every 3 months for 2 years, then every 6 months until 5 years.

03

Conditions studied

  • Core Binding Factor Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • GENERAL MYELOMATCH CRITERIA: Patients must be registered to the Master Screening and Reassessment Protocol, MYELOMATCH, and assigned to this protocol by the MATCHBox Treatment Verification Team
  • GENERAL MYELOMATCH CRITERIA: Participants must not have received prior anti-cancer therapy for AML or myelodysplastic syndrome (MDS)

    • Note: Hydroxyurea to control the white blood cell count (WBC) and cytarabine up to 1g for urgent cytoreduction is allowed.
    • Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility
  • GENERAL MYELOMATCH CRITERIA: Participants must not receive any cytarabine-containing therapy other than up to 1g of cytarabine, which is allowed for urgent cytoreduction. Hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide is allowed
  • Diagnosis of AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 or AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11. No FLT3 mutation (these patients should be considered for a FLT3-focused MYELOMATCH study)
  • Secondary CBF-AML (e.g., prior pre-leukemic hematologic or history of chemotherapy/radiation therapy) is allowed.
  • No prior AML or MDS-directed therapy except for urgent treatment of leukocytosis with leukapheresis, cytarabine, and hydroxyurea, Prior intrathecal chemotherapy for central nervous system (CNS) involvement of AML is permitted
  • Age 18-59 years
  • (ECOG) performance status ≤ 3
  • Total ≤ 1.5 x (ULN) (unless patient has a history of Gilbert syndrome and direct bilirubin is ≤ 1.5 x ULN)
  • (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x upper limit of normal (ULN)
  • (GFR) ≥ 30 mL/min/1.73m\^2
  • Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of only, a negative urine or serum pregnancy test done ≤ 7 days prior to registration is required
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Participants with CNS disease are eligible for this trial and will be treated according to institutional guidelines with intrathecal chemotherapy for this aspect of their disease
  • Patients with known infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class II or better
  • No known medical condition causing an inability to swallow oral formulations of agents
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Regimen 1 (gemtuzumab ozogamicin 7+3)

    Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Procedure: Echocardiography Test · Drug: Gemtuzumab Ozogamicin · Procedure: Multigated Acquisition Scan

  • Experimental
    Regimen 2 (Venetoclax, 7+3)

    Patients receive venetoclax orally (PO) once daily (QD) on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Venetoclax

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • Given IV

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • DrugDaunorubicinStudies of DaunorubicinDaunorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem

  • ProcedureEchocardiography Test

    Undergo echocardiography

    Also known as: EC, Echocardiography

  • DrugGemtuzumabStudies of GemtuzumabGemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA scan

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • Given PO

    Also known as: ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Complete remission without measurable residual disease (CRMRD-)

    MRD will be evaluated by Molecular Diagnostics Network flow cytometry and will be defined at a threshold of ≤ 10\^-3.

    Time frame: At end of induction (Up to 28 days)

Secondary outcomes

  1. Rate of complete remission (CR)

    Defined as the number of evaluable patients achieving a response of CR per European Leukemia Network (ELN) 2022 criteria at the end of treatment divided by the total number of evaluable patients. Rates of response will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for CR rate within each arm along with 95% confidence intervals using the Clopper-Pearson method.

    Time frame: At the end of treatment (Up to 28 days)

  2. Rate of composite CR

    Defined as the number of evaluable patients achieving a response of CR or complete remission with incomplete hematologic recovery (CRi) or complete remission with partial hematologic recovery (CRh) per ELN 2022 criteria at the end of treatment divided by the total number of evaluable patients. Rates of response will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for CR rate within each arm along with 95% confidence intervals using the Clopper-Pearson method.

    Time frame: At the end of treatment (Up to 28 days)

  3. Overall survival (OS)

    The distribution of OS will be estimated using method of Kaplan-Meier. The median OS and 95% confidence interval will be reported.

    Time frame: From registration until death due to any cause, up to 5 years

  4. Event free survival (EVS)

    Induction failure is defined as not achieving either CR, CRh or CRi by after induction therapy. The distribution of EFS will be estimated using method of Kaplan-Meier, and compared using log-rank tests. The median EFS and the corresponding 95% confidence interval will be reported.

    Time frame: From randomization to induction failure, hematologic relapse from CR/CRh/CRi or death from any cause, whichever occurs first, up to 5 years

  5. Cumulative incidence of relapse (CIR)

    The distribution of CIR will be estimated using Fine-Gray model and reported via hazard ratios and 95% confidence interval with p values.

    Time frame: From the date of achievement of a remission until the date of hematologic relapse, up to 5 years

  6. Cumulative incidence of death (CID)

    The distribution of CID will be estimated using Fine-Gray model and reported via hazard ratios and 95% confidence interval with p values.

    Time frame: From the date of achievement of a remission to death without prior relapse, up to 5 years

  7. Rate of early death at 30 days (ED-30)

    ED-30 is defined as the total number of patients who died on or before day 30 from randomization divided by the total number of evaluable patients. Rate of early death at day 30 will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for ED-30 rate within each arm along with 95% confidence intervals using the Clopper-Pearson method.

    Time frame: At 30 days

  8. Rate of early death at 60 days (ED-60)

    ED-60 is defined as the total number of patients who died on or before day 60 from randomization divided by the total number of evaluable patients. Rate of early death at day 60 will be compared between treatment arms using a chi-square test (or Fisher's exact test as needed). Point estimates will be generated for ED-60 rate within each arm along with 95% confidence intervals using the Clopper-Pearson method.

    Time frame: At 60 days

  9. Incidence of adverse events

    As per national Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. The incidence of severe (grade 3+) adverse events or toxicities will be described for each treatment arm and will also be compared between the arms. Fisher's exact tests will be used to quantitatively compare the incidence of severe as well as specific toxicities of interest between the treatment arms and we will graphically assess differences in maximum grades observed for toxicities between the arms.

    Time frame: Up to 5 years

  10. Evaluate mutant RAS and mutant KIT as predictive biomarkers for CRMRD- rate

    In cohort 1, subgroup analysis will be conducted to evaluate the treatment effect among RAS mutated patients using Kaplan Meier methods and log-rank tests; similar subgroup analysis will be done among KIT mutated patients.

    Time frame: Up to 5 years

07

Study locations

81 of 81 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

11 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2027, 13 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 13 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

Start moved once since we started tracking on Sep 25, 2026: Feb 2027 → Sep 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 9, 2025
StartActual
Sep 28, 2026was Feb 2027
Primary completionEst.
Nov 25, 2027
CompletionEst.
Nov 25, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added — first site in Puerto Rico
Show 16 added (14 United States, 2 Puerto Rico)
  • University of New Mexico Cancer Center · Albuquerque, United States
  • Centro Comprensivo de Cancer de UPR · San Juan, Puerto Rico
  • San Juan City Hospital · San Juan, Puerto Rico
  • UC San Diego Moores Cancer Center · La Jolla, United States
  • Dana-Farber Cancer Institute · Boston, United States
  • Rhode Island Hospital · Providence, United States
  • Our Lady of the Lake Physician Group · Baton Rouge, United States
  • Logan Health Medical Center · Kalispell, United States
  • VCU Massey Comprehensive Cancer Center · Richmond, United States
  • Rush MD Anderson Cancer Center · Chicago, United States
  • University of Chicago Comprehensive Cancer Center · Chicago, United States
  • UC Comprehensive Cancer Center at Silver Cross · New Lenox, United States
  • University of Chicago Medicine-Orland Park · Orland Park, United States
  • UChicago Medicine Northwest Indiana · Crown Point, United States
  • University of Illinois · Chicago, United States
  • Community Hospital of Anaconda · Anaconda, United States
across 10 updates, Sep 29, 2026 – Nov 4, 2026
Start date
Feb 2, 2027→Sep 28, 2026 (actual)
Oct 1, 2026
Show all 11 updates
  1. Nov 4, 2026
    1 site added
    Show site
    • Community Hospital of Anaconda · Anaconda, United States
  2. Oct 30, 2026
    1 site added
    Show site
    • University of Illinois · Chicago, United States
  3. Oct 29, 2026
    4 sites added
    Show 4 added (4 United States)
    • University of Chicago Comprehensive Cancer Center · Chicago, United States
    • UC Comprehensive Cancer Center at Silver Cross · New Lenox, United States
    • University of Chicago Medicine-Orland Park · Orland Park, United States
    • UChicago Medicine Northwest Indiana · Crown Point, United States
  4. Oct 28, 2026
    1 site added
    Show site
    • Rush MD Anderson Cancer Center · Chicago, United States
  5. Oct 26, 2026
    1 site added
    Show site
    • VCU Massey Comprehensive Cancer Center · Richmond, United States
  6. Oct 20, 2026
    1 site added
    Show site
    • Logan Health Medical Center · Kalispell, United States
  7. Oct 6, 2026
    1 site added
    Show site
    • Our Lady of the Lake Physician Group · Baton Rouge, United States
  8. Oct 5, 2026
    3 sites added
    Show 3 added (3 United States)
    • UC San Diego Moores Cancer Center · La Jolla, United States
    • Dana-Farber Cancer Institute · Boston, United States
    • Rhode Island Hospital · Providence, United States
  9. Oct 1, 2026
    Start date Feb 2, 2027→Sep 28, 2026 (now actual)
    + 1 other change: verification date
  10. Sep 30, 2026
    2 sites added — first site in Puerto Rico
    Show 2 added (2 Puerto Rico)
    • Centro Comprensivo de Cancer de UPR · San Juan, Puerto Rico
    • San Juan City Hospital · San Juan, Puerto Rico
  11. Sep 29, 2026
    1 site added
    Show site
    • University of New Mexico Cancer Center · Albuquerque, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06917911
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Sep 28, 2026
Primary completion
Nov 25, 2027 (estimated)
Completion
Nov 25, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Celalettin Ustun
principal investigator · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemtuzumab · Venetoclax

Start the discussion